Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, continues to empower parents with increased access to prenatal testing. SneakPeek, the #1 OBGYN-recommended ...

Myriad Genetics and agency partner S50 Health educated OBGYNs and their patients in a campaign called “Getting Ahead of ...

22, 2024 — A study suggests that menopausal hormone therapy (MHT) might have moderate effects on brain health, but this depends ... 25, 2024 — Women worldwide could see better treatment ...

The World Bank has committed to giving Bangladesh $400 million for implementing the next five-year plan for the health sector ...

HighlightsThird quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on ...

CHCH-TV started broadcasting in 1954 and is proud to be the news leader for Hamilton and the surrounding Halton and Niagara ...

This is actually something I will be treating my mum to this Christmas - so if you're reading this click out now! They're ...

Notes from several investment houses indicate that the insurance giant will no longer cover genetic tests for behavioral health, which includes Myriad's GeneSight, beginning Jan. 1, 2025.

This is the second edition of Giant Leap’s deep dive series, where its investment team explores the technologies and approaches addressing global problems of climate, health and people with commercial ...

Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad’s proprietary and clinically differentiated mental health medication test, GeneSight, and is seeking ...

Stephens analyst Mason Carrico notes that Myriad Genetics (MYGN ... no longer cover multi-panel genetic tests for behavioral health diagnoses. The announcement lists codes that will be denied ...

Call it Trump Tummy, Ballot Blues, Election Ute, whatever you want—people are experiencing unusual symptoms as they head to ...